Press Releases

Date Title  
Toggle Summary Natera Presents Breast Cancer Data at SABCS Showing Ability of Signatera (RUO) to Detect Molecular Residual Disease Up to Two Years Prior to Clinical Relapse and Predict Treatment Response
Study Demonstrates Utility of Assay in Neoadjuvant and Adjuvant Treatment Settings SAN CARLOS, Calif. , Dec. 6, 2018 /PRNewswire/ -- Natera , Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of cell-free DNA, presented data from two studies this week at the 2018 San
Toggle Summary Natera Achieves Enrollment Goal of 20,000 Patients in SMART Study
Primary study results on the 20,000 patients anticipated in 2019 to validate the clinical utility of routine screening for microdeletion genetic conditions SAN CARLOS, Calif. , Nov. 29, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that
Toggle Summary Natera Receives Unique Z-Code for Its Kidney Transplant Rejection Monitoring Test
Represents a Key Milestone Towards Achieving Medicare Reimbursement SAN CARLOS, Calif. , Nov. 28, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the assignment of a unique Z-code for the company's kidney transplant rejection assay,
Toggle Summary Natera Reports Third Quarter 2018 Financial Results
SAN CARLOS, Calif. , Nov. 8, 2018 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the third quarter ended September 30, 2018 , and provided an update on recent business
Toggle Summary Natera Announces Third Quarter 2018 Earnings Conference Call
SAN CARLOS, Calif. , Nov. 1, 2018 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its third quarter ended Sept. 30, 2018 , after the market close on Nov. 8, 2018 .
Toggle Summary Natera and Neon Therapeutics Announce Clinical Trial Collaboration to Assess Treatment Response to Personal Cancer Vaccine
Combines Neon's Personal Neoantigen Vaccine and Signatera (RUO) Circulating Tumor DNA Biomarker in Metastatic Non-Small Cell Lung Cancer Trial SAN CARLOS, Calif. , & CAMBRIDGE, Mass. , Oct. 18, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, and  Neon
Toggle Summary Natera Signs Agreement with Bristol-Myers Squibb to Investigate Signatera™ ctDNA Assay as a Potential Biomarker for Opdivo (nivolumab) in a Prospective Phase 2 Adjuvant Non-Small Cell Lung Cancer Clinical Trial
First Study Using ctDNA-based Minimal Residual Disease Assessment for Immunotherapy in the Adjuvant NSCLC Setting SAN CARLOS, Calif. , Sept. 13, 2018 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an agreement with Bristol-Myers Squibb to use
Toggle Summary Natera and Fox Chase Cancer Center to Collaborate on Kidney Cancer Study
SAN CARLOS, Calif. , Aug. 15, 2018 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, has partnered with Fox Chase Cancer Center , one of the leading cancer centers in the United States , to assess the company's Signatera™ (Research-Use Only) customized
Toggle Summary Natera Reports Second Quarter 2018 Financial Results
SAN CARLOS, Calif. , Aug. 8, 2018 /PRNewswire/ --  Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the second quarter ended June 30, 2018 and provided an update on recent business progress.
Toggle Summary Natera Clinical Study Validates New Biomarker for Aneuploidy and Adverse Pregnancy Outcomes
Study Highlights Proprietary Technology for Fetal Fraction Measurement in Non-Invasive Prenatal Testing SAN CARLOS, Calif. , Aug. 7, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced new study results demonstrating that fetal fraction, as

Footer disclaimer

Footer disclaimer

© Natera 2019. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.